<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150289</url>
  </required_header>
  <id_info>
    <org_study_id>20192475</org_study_id>
    <nct_id>NCT04150289</nct_id>
  </id_info>
  <brief_title>A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat</brief_title>
  <acronym>RECOMM</acronym>
  <official_title>A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe current treatment patterns in the real-world setting among&#xD;
      patients with multiple myeloma who are initiating treatment with (or changing treatment to)&#xD;
      panobinostat and explore the associations with baseline patient characteristics, healthcare&#xD;
      resource utilization, and clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Looking for patient reproted response to treatment with panobinostat</description>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farydak</intervention_name>
    <description>non-interventional study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be any adult who is clinically diagnosed with multiple myeloma&#xD;
        who is actively taking panobinostat.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Clinical diagnosis of multiple myeloma that meets published diagnostic criteria&#xD;
&#xD;
          -  Initiating panobinostat within 60 days of enrollment&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Availability of documentation from the patient's medical records regarding previous&#xD;
             myeloma treatment, response, and duration of response&#xD;
&#xD;
          -  Willing and able to complete the PRO questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with any B-cell malignancy other than myeloma&#xD;
&#xD;
          -  Estimated life expectancy &lt;6 months&#xD;
&#xD;
          -  Currently enrolled in any interventional clinical trial at study entry (note: patients&#xD;
             who enroll in an interventional clinical trial after enrollment may remain in the&#xD;
             registry)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Travis</last_name>
    <phone>803-329-7772</phone>
    <email>ltravis@ccorn.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra Litwak</last_name>
    <phone>8054797793</phone>
    <email>dlitwak@securabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>American Health Network Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kisha Horan</last_name>
      <phone>317-462-1826</phone>
      <email>kisha_horan@ahni.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Nevada Cancer Research Foundation and Optum Cancer Care</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Littlefield</last_name>
      <phone>702-384-0013</phone>
      <email>v.littlefield@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Khawaja Jahangir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Howe</last_name>
      <phone>704-342-1900</phone>
      <email>joe.howe@djlresearch.com</email>
    </contact>
    <investigator>
      <last_name>Justin Favaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Oncology Specialists</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Roberts</last_name>
      <phone>704-659-7833</phone>
    </contact>
    <investigator>
      <last_name>William Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Burke</last_name>
      <phone>717-334-4033</phone>
      <email>terry@gettysburgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Satish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Cancer Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Paretti</last_name>
      <email>clindir@coastalcancercenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Travis</last_name>
      <phone>803-329-7772</phone>
      <email>ltravis@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Sashi Naidu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Farydak</keyword>
  <keyword>panobinostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

